教育背景

2004-2010中科院上海生命科学研究院，生物化学与分子生物学专业，博士

2000-2004浙江大学生命科学学院，生物技术专业，本科

研究经历

2018-现浙江大学转化医学研究院/浙江大学医学与阿附属第一医院，研究员

2010-2017麻省理工学院，博士后

代表性论文

1. Feng M, Jin JQ, Xia L, et al., Feng YX*, Zhu D*. 2019. Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating T_reg cells. Science Advances 08 May 2019: Vol. 5, no. 5 (*co-corresponding author)    

2. Feng YX, Jin DX, Sokol ES, Reinhardt F, Miller DH, Gupta PB. 2017. Cancer-specific PERK signaling drives invasion and metastasis through CREB3L1. Nature Communications 8:1079     

3. Sokol ES*, Feng YX*, Jin DX*, Tizabi MD, Miller DH, et al. 2017. SMARCE1 is required for the invasive progression of in situ cancers. PNAS 114:4153-8 (*co-first author)  

4. Feng YX, Sokol ES, Del Vecchio CA, Sanduja S, Claessen JH, et al. 2014. Epithelial-to-mesenchymal transition activates PERK-eIF2alpha and sensitizes cells to endoplasmic reticulum stress. Cancer Discovery 4:702-15

5. Feng YX, Sokol ES, Gupta PB. 2014. The endoplasmic reticulum may be an Achilles' heel of cancer cells that have undergone an epithelial-to-mesenchymal transition. Molecular & Cellular Oncology 1:e961822

6. Feng YX, Wang T, Deng YZ, Yang P, Li JJ, et al. 2011. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology 53:483-92

7. Feng YX, Zhao JS, Li JJ, Wang T, Cheng SQ, et al. 2010. Liver cancer: EphrinA2 promotes tumorigenicity through Rac1/Akt/NF-kappaB signaling pathway. Hepatology51:535-44

在研项目

1.国家海外高层次人才项目，主持

2.国家自然科学基金面上项目，主持

3.浙江省自然科学基金重大项目，支持

4.科技部重点研发项目，参与

5.浙江省领军型创新创业团队项目，参与